What is Marty Makary’s FDA voucher program?

It is a proposal to let sponsors use vouchers to seek faster FDA decisions when data supports speed. It differs from traditional priority review by tying acceleration to a voucher framework. Legal questions remain about who authorizes it and how it fits current law, which could affect how quickly sponsors can file and get decisions.

How could obesity drug review delays affect LLY and NVO?

Delays can push U.S. launch dates, shift revenue timing, and complicate payer talks. For high-demand GLP-1 therapies, even small extensions matter. Investors should watch FDA meeting updates, labeling discussions, and any new safety analyses that could add work. Marty Makary’s plan could help later, but legal clarity is the near-term driver.

What should investors watch next amid the voucher uncertainty?

Look for an FDA statement clarifying who signs off on the program, potential Advisory Committee meetings, and company filings that update review timelines. Earnings in early February 2026 may include color on interactions with reviewers. Keep an eye on technical signals too, since policy headlines can trigger quick moves before fundamentals shift.

Are LLY and NVO still buys after the policy news?

Positioning depends on time horizon. LLY trades at a higher multiple, so timelines matter more. NVO is cheaper but overbought short term. Analysts skew positive on LLY and more neutral on NVO. A prudent approach is staged entries, attention to catalysts, and quick reassessment if delays spread or legal questions persist.

Global Market Insights

January 17: Makary’s FDA Voucher Plan Faces Legal Heat; LLY, NVO at Risk

ByDanny Kontos January 17, 2026January 17, 2026

Marty Makary is under pressure as legal questions and process hiccups hit the FDA voucher program for expedited drug approvals. On January 17, reports flagged uncertainty over who can authorize the plan and why two early applications were delayed. That policy overhang could slow obesity drug timelines for Eli Lilly (LLY) and Novo Nordisk (NVO) in the U.S. market. We break down the risks, what the delays signal, and how this could affect valuations, trading levels, and near-term catalysts for retail investors.